Ramos et al. analyzed immune responses to known tumor-associated antigens in the peripheral blood of patients before and after CD19 CAR-T cell infusion, and they observed no differences in the frequency of precursor T cells responding to these antigens before and after infusion [92]. The gene discussed is CD19; the disease is neoplasm.